- A multinational, phase 3 clinical trial – TALAPRO-2 – tested whether the combination of two medicines, talazoparib and enzalutamide, may improve clinical outcomes in adult men with metastatic castration-resistant prostate cancer.
- Treatment with talazoparib and enzalutamide resulted in a 37% reduced risk of cancer progression or death, compared to treatment with placebo and enzalutamide.
- The Food and Drug Administration (FDA)’s decision on whether or not this combination therapy may be used to treat men with metastatic castration-resistant prostate cancer is expected in 2023.
According to the
Androgens (male hormones) such as testosterone help prostate cancer cells grow. Sometimes, prostate cancer continues to grow even when testosterone levels in the blood are suppressed. This is known as
If the cancer spreads from the prostate gland to other parts of the body, such as the lymph nodes and bones, it is classified as metastatic castration-resistant prostate cancer.
In recent years, there have been great improvements in the treatment of metastatic castration-resistant prostate cancer. Despite this progress, currently available treatments have a short-duration effect, and the cancer can start growing again after treatment.
Now, researchers at Pfizer have developed a novel therapy for metastatic castration-resistant prostate cancer by combining two existing medications, talazoparib (Talzenna) and enzalutamide (Xtandi).
They tested the efficacy and safety of this combination therapy in a phase 3 trial, TALAPRO-2.
The results of the clinical trial were presented at the 2023 ASCO Genitourinary Cancers Symposium by Dr. Neeraj Agarwal, professor of oncology and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and lead investigator for…
Read the full article here